Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM versus NIRAVAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM versus NIRAVAM.
LORAZEPAM vs NIRAVAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
2-3 mg orally or IV, 3-4 times daily; maximum 10 mg/day. For anxiety, 0.5-2 mg orally 2-3 times daily. For procedural sedation, IV: 0.044 mg/kg or 2 mg total, may repeat.
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours. Clinically significant for once-daily dosing; may accumulate in elderly or hepatic impairment.
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateLorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."
Clinical Note
moderateLorazepam + Clemastine
Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Primarily renal excretion as glucuronide conjugates; less than 1% excreted unchanged. Approximately 60-80% eliminated in urine, with 15-20% in feces.
Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine."